Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:3523057.
doi: 10.1155/2016/3523057. Epub 2016 Jan 18.

Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses

Lyubomir A Dourmishev  1 , Dimitrina V Guleva  1 , Ljubka G Miteva  1
Affiliations
Review

Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses

Lyubomir A Dourmishev et al. Int J Inflam. 2016.

Abstract

Intravenous immunoglobulins (IVIGs), a mixture of variable amounts of proteins (albumin, IgG, IgM, IgA, and IgE antibodies), as well as salt, sugar, solvents, and detergents, are successfully used to treat a variety of dermatological disorders. For decades, IVIGs have been administered for treatment of infectious diseases and immune deficiencies, since they contain natural antibodies that represent a first-line defense against pathogens. Today their indication has expanded, including the off-label therapy for a variety of autoimmune and inflammatory diseases. In dermatology, IVIGs are administered for treatment of different disorders at different therapeutic regimens, mostly with higher doses then those administered for treatment of infectious diseases. The aim of this prospective review is to highlight the indications, effectiveness, side effects, and perspectives of the systemic treatment with IVIGs for patients with severe, life-threatening, and resistant to conventional therapies autoimmune or inflammatory dermatoses.

PubMed Disclaimer

References

    1. Kazatchkine M. D., Kaveri S. V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. The New England Journal of Medicine. 2001;345(10):747–755. doi: 10.1056/nejmra993360. - DOI - PubMed
    1. Andersson J., Skansen-Saphir U., Sparrelid E., Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clinical & Experimental Immunology. 1996;104:10–21. - PubMed
    1. Hurez V., Kaveri S. V., Mouhoub A., et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg) Therapeutic Immunology. 1994;1(5):269–277. - PubMed
    1. Marchalonis J. J., Kaymaz H., Dedeoglu F., Schluter S. F., Yocum D. E., Edmundson A. B. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(8):3325–3329. doi: 10.1073/pnas.89.8.3325. - DOI - PMC - PubMed
    1. Tha-In T., Bayry J., Metselaar H. J., Kaveri S. V., Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends in Immunology. 2008;29(12):608–615. doi: 10.1016/j.it.2008.08.004. - DOI - PubMed

LinkOut - more resources